AGENUS INC Proceeds from Debt, Net of Issuance Costs
AGENUS INC (AGEN) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-08-07
- AGENUS INC proceeds from debt, net of issuance costs for the quarter ending 2026-06-30 was $0.00.
- AGENUS INC proceeds from debt, net of issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC proceeds from debt, net of issuance costs for the quarter ending 2025-12-31 was $10.00M, a 50.00% decline year-over-year.
- AGENUS INC proceeds from debt, net of issuance costs for the quarter ending 2025-09-30 was $0.00.
- AGENUS INC proceeds from debt, net of issuance costs for fiscal 2025 was $12.50M, a 37.50% decline from fiscal 2024.
- AGENUS INC proceeds from debt, net of issuance costs for fiscal 2024 was $20.00M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $10.00M derived: sum of 3 quarters · filed 2026-08-07 | $10.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $10.00M derived: sum of 2 quarters · filed 2026-05-11 | $10.00M derived: sum of 3 quarters · filed 2026-05-11 | $10.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $10.00M derived: sum of 2 quarters · filed 2026-03-16 | $10.00M derived: sum of 3 quarters · filed 2026-08-07 | $12.50M 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-07 | $2.50M 10-Q · filed 2025-11-10 | $22.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $2.50M 10-Q · filed 2026-08-07 | $22.50M derived: sum of 3 quarters · filed 2026-08-07 | $22.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.50M 10-Q · filed 2026-05-11 | $22.50M derived: sum of 2 quarters · filed 2026-05-11 | $22.50M derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $20.00M derived: sum of 2 quarters · filed 2026-03-16 | $20.00M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |